Citius Pharmaceuticals (NASDAQ:CTXR) Shares Break Above 50-Day Moving Average – Time to Sell?

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $0.54 and traded as high as $0.55. Citius Pharmaceuticals shares last traded at $0.5411, with a volume of 201,092 shares traded.

Analysts Set New Price Targets

A number of research firms recently commented on CTXR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday, September 21st. HC Wainwright reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th. Finally, Citigroup reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Citius Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $6.00.

Citius Pharmaceuticals Trading Up 7.9%

The company has a quick ratio of 0.40, a current ratio of 0.84 and a debt-to-equity ratio of 0.08. The firm has a 50 day moving average price of $0.54 and a two-hundred day moving average price of $0.66. The company has a market cap of $14.85 million, a price-to-earnings ratio of -0.32 and a beta of 1.00.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. As a group, equities analysts forecast that Citius Pharmaceuticals, Inc. will post -2.03 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Citius Pharmaceuticals stock. BlackRock Inc. acquired a new stake in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned approximately 0.25% of Citius Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for critical care, oncology and other areas with significant unmet medical needs. The company is headquartered in Cranford, New Jersey, and has primarily focused its development and commercialization activities on the U.S. healthcare market.

Citius’ lead product candidate has been Mino-Lok, an antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while allowing the catheter to remain in place.